Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidates

TLDR Jasper Therapeutics completes Kira merger, raises $132M for pipeline growth. Combined firm targets PNH, transplant, and autoimmune disease programs ahead. KP-104 renal trial data and FDA meetings expected in late 2026. Briquilimab and KP-701 advance toward BLA and IND filing...